Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously
treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for
these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3
week cycle. The objective of the protocol is to determine the highest dose of imexon which
can be given with a full dose of docetaxel, and to provide information to enable the design
of a future study focused on one or more specific cancer types.